Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Australia’s Cochlear Ltd. won breakthrough FDA approval today for its Nucleus Hybrid L24 implantable hearing system, the 1st device of its kind on the U.S. market.
The technology is the 1st implantable hearing aid approved for adults who can still hear low-frequency sounds but can’t make out high-frequency sounds in either ear due to damage in the inner ear. Read more
San Francisco startup Oculeve Inc. closed a $16.6 million funding round in supports of its implantable technology for treatment of dry eye disease.
The money was raised through sales of equity to 8 unnamed investors, according to an SEC filing. Around this same time last year Oculeve had reported $7.6 million raised from 9 investors and in October 2012 the company reportedly raised $7.6 million from 8 investors. The company has reportedly raised around $33.2 million since 2011. Read more
Augmedix calls itself the “first and largest Google Glass startup poised to revolutionize healthcare,” touting a $3.2 million venture funding round and a move to a larger headquarters in San Francisco.
Now at 36 employees, the 2-year-old company is working on a flagship product that would free physicians from the “flood of data and documentation” they face on a regular basis. Augmedix’s service platform allows doctors to use Google Glass to push information to patient records and retrieve information verbally. Read more